Directed new share issue in Oncopeptides AB (SE) — SEK 727 million

Carnegie acted as joint bookrunner in the directed new share issue of 5,015,000 shares at a subscription price of SEK 145 per share. Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. June 2019.